Company Overview
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +103.54% |
| 6 Months: | +95.75% |
| 3 Months: | +38.16% |
| 1 Month: | +34.52% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)59.84 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MPLT MapLight Therapeutics, Inc. R2K | 37.33 | -8.46 | $1.59B | 0.00% | -36.50% | -80.95% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating Income | - | - | -20.89M | -23.54M | - | -31.50M | -64.50M |
| Net Income | -18.93M | -18.40M | -19.02M | -22.34M | -29.85M | -29.42M | -60.67M |
| Diluted EPS | - | - | -25.08 | -29.33 | - | -37.18 | -1.34 |
| R&D Expense | - | - | 16.81M | 19.79M | - | 27.09M | 53.68M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Income | -82.95M | -169.08M |
| Net Income | -77.58M | -161.15M |
| Diluted EPS | -105.38 | -18.56 |
| R&D Expense | 68.52M | 138.35M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | - | 136.92M | 479.51M |
| Total Equity | -117.58M | -193.63M | 458.37M |
| Cash & Equivalents | - | 38.25M | 46.73M |
| Total Liabilities | - | 21.72M | 21.14M |
| Current Liabilities | - | 15.92M | 16.23M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -78.81M | -138.14M |
| Investing Cash Flow | -80.79M | -323.21M |
| Financing Cash Flow | 118.06M | 469.82M |
| Capital Expenditure | -770.00K | -473.00K |
| Free Cash Flow | -79.58M | -138.61M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
| ROE % | 40.1% | -35.2% |
| ROCE % | -68.6% | -36.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Novo Holdings A/S | 8.65% | 3.69M | $132.02M |
| 2 | FCPM III Services B.V. | 7.57% | 3.23M | $115.54M |
| 3 | T. Rowe Price Investment Management, Inc. | 6.57% | 2.80M | $100.34M |
| 4 | Goldman Sachs Group Inc | 4.68% | 1.99M | $71.44M |
| 5 | Blackrock Inc. | 3.14% | 1.34M | $47.98M |
| 6 | Blue Owl Capital Holdings LP | 2.36% | 1.01M | $36.02M |
| 7 | Nan Fung Group Holdings Limited | 2.28% | 971.25K | $34.78M |
| 8 | 5AM Venture Management, LLC | 2.23% | 950.01K | $34.02M |
| 9 | Sanofi | 2.14% | 912.04K | $32.66M |
| 10 | Vanguard Capital Management LLC | 1.69% | 719.82K | $25.78M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MPLT
Maplight Therapeutics (NASDAQ:MPLT) Trading Down 5.4% - Here's What Happened - MarketBeat
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPLTJOQjBVY1FhOFJHNFRmdUtXUU1TcnhmcVNLV1luVnUwQ210VnFxdTBTMjZXQ05SX05tZDdqc0JMX1NfU3NhazlTeVlWWXQ0ZjNBeTFvME5mbWp5anRibmxzcE9CRmZMRkRNZV9tUHJPU1p1bElnamtYNXBYWkllTW9fWkVaMzE3Mk96T0…
Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOSk1GalNCTXAyamJ3VDdubjhoSmNWOFgyUnJMcUhkZm9zWENiSmFPckgySUc3YnJUakprejFNRGNFV2R4eGE5MzdhYW1ZZV9HR0ppaWFEblJMNUhsbkN6bGdPSVk4b0h4WHF6UThSVWNlbWkyWXBLS0JsM2RRZExPM2NiLTVfb2hTVFpYNV…
$MPLT stock is up 11% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNQnlIT1FNemUweFBhaTR6ajF0cXpzTC1wMDVsaDkyZ1F3MUI1WHNDTFg4VWtlanY0TjNVMkNIbVVVYVB6WmRROEJMNk5sVm9kLUV4M2YzUmRnQm9MVjRCTVJZSFRSQTNYZVpwUlN3VDIyWnYxbThnOEZwVXNhUXZCeDIteHktX2NVeko3TE…
Biotech Stocks At 52-Week Highs: TRAX, BBIO, MNPR, TXG, MPLT - RTTNews
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOc1F1MmEzOGJ3T1VBaHJ1YVdPMWt3d3VtQTQtX1ZQS1lXOXRUWmw3aE9FTWRJYnlUdS1oSVh6QUtkOVdtbWlLMmo0RjUweWhSSDNGZUo5dlVQa0FSd0FGaEloNlR4d21wYnFWUTF1c1kzc1pzaENOSEpId2EtbV9aVE1hVk5SaWY2bEFIVm…
What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNN0FfUUxfRFJwd3JPUmVnTUtTU2c5cHVSLVJzcktpai1tMTRMcTlLWXE3bGk1X3MxaklsR3NJZld1NTA2QjlZQjlJVkRwcV9ULU9HbE5ucWtBblUwbk5nN3JJQUlLMjM1VWRyRUVNTllaZXBaczlEbDd3cGJTVlhPNEROSjhyX3BwWHpjcD…
Tonix, MapLight are new Strong Buys at Raymond James on upcoming catalysts - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxQdFc5V0tHTllQemN5YXNnM0F6dk9vcmRoYkllSkQ2ZFAzTENxa0xrM003NTFGdGpGNlRibmdyVXA3QWdZX1M3MkNYTlVveGJQT0kxN0ZrVEtCYVZoN0ltUnNtUlFpY1RPZWEwZ0NYQlo1cEtnaUlCNU9fLU9mbHVtVlVTTkRMcy1SaGc?oc…
MPLT — Frequently Asked Questions
What is the current share price of MapLight Therapeutics, Inc. (MPLT)?
As of 2026-07-15 16:51 PDT, MapLight Therapeutics, Inc. (MPLT) trades at $37.33 on NasdaqGS. Its 52-week range is $12.81 to $39.80.
What is the market capitalisation of MPLT?
MapLight Therapeutics, Inc. (MPLT) has a market capitalisation of $1.59B on NasdaqGS.
What is the P/E ratio of MPLT?
MPLT trades at a trailing price-to-earnings (P/E) ratio of -8.46. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 4.05.
What is the return on equity (ROE) of MPLT?
MPLT has a return on equity (ROE) of -80.95%. Its return on capital employed (ROCE) is -36.50%.
Is MPLT a good stock to buy?
This page provides a data-driven analysis of MapLight Therapeutics, Inc. (MPLT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.